Navigation Links
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
Date:5/7/2008

ing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurre
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces First Quarter 2008 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & ... MicroCap Conference on Thursday, May 30, 2013, in ... The Company,s presentation is scheduled to begin ... live webcast. To access the webcast, go to www.atossagenetics.com ...
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
(Date:5/19/2013)... May 19, 2013 The muscles in ... their functionality and one of the biggest and most ... nervous system. The peripheral system comprises of peripheral nerves ... cord. These nerves ensure that the limbs and hands, ... when these nerves get damaged due to trauma or ...
(Date:5/19/2013)... According to a new market research ... – 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), ... Contact IS, Infrared, X-Ray) And Geography" published by ... $8.00 billion in 2012 and is expected to ... CAGR of 3.84% from 2013 to 2018. In ...
(Date:5/19/2013)... 2013 The report “Feed Additives Market ... Forecasts up to 2017” published by MarketsandMarkets, defines and ... and forecasting of the global volume and revenue for ... and restraining factors for the global market with analysis ... The market is segmented and revenue is forecasted on ...
(Date:5/19/2013)... May 19, 2013 Americans live closer ... the newest American Veterinary Medical Association (AVMA) U.S. Pet ... dog owners consider their dog a member of the ... said as much five years earlier. , According to ... of the national income dedicated to pets has increased ...
(Date:5/19/2013)... The Fat Loss Code program developed by Shawn ... help people get in shape, and gain a healthy life ... also is a natural fat loss system that provides people ... this fat loss diet program claimed that The Fat Loss ... keep body fat off long-term. After Shawn Stevenson launched this ...
Breaking Medicine News(10 mins):Health News:Ultimate Neuropathy Support System Launched by Neuracel - Reaching New Heights in Herbal Medication for Peripheral Neuropathy 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Weight Loss Secrets | How “The Fat Loss Code” Helps People Gain A Healthy Life And Get In Shape - Health Review 2
... Incorporated Introduces Pesticide-Free Treatment that Safely ... Eliminates Head Lice, Eggs and Nits, WHITE PLAINS, N.Y., ... conditions among children, only second to the common,cold.(1) There are about ... miss approximately 12 to 24 million school days annually.(3),But, now parents ...
... Wis., April 3, 2008 Mach One,Corporation, ... tests prior to large scale manufacturing of its ... "A highly qualified scientist from BioQual spent a ... a technology transfer and,memorializing the protocols for manufacture ...
... 2008 A new study presented today ... researchers for Scientific,Food Solutions,( http://www.scientificfoodsolutions.com/pages/clinicals.html ) demonstrates,that ... C with,Bioperine(R), provides 275 percent faster absorption ... President of Scientific Food Solutions said, "Body,weight ...
... Integration of AccuNurse(R) voice-assisted care with Elite Clinical,Software brings ... ... Retirement Communities, PITTSBURGH, April 3, 2008 Vocollect ... a strategic partnership,that includes integrating AccuNurse voice-assisted care with ...
... radiation and pesticides as probable causes , , THURSDAY, April ... risk of miscarriage, apparently the result of being exposed ... of work, a new study found. , Not only ... risks, but veterinary offices and labs need to be ...
... Velocity(TM) miniBTE and ion(TM) 400 to be officially introduced in April ... ... CITY, April 3, 2008 Sonic,Innovations, Inc. (Nasdaq: SNCI ) continues ... products -- the Velocity(TM),miniBTE and the ion(TM) 400. The products will be ...
Cached Medicine News:Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 2Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2Health News:Comfort C(R) Provides Significantly Higher Absorption Than Other Leading Brand 2Health News:Answers On Demand (AOD) and Vocollect Healthcare Systems Announce a 'First in the Industry' Strategic Partnership 2Health News:Answers On Demand (AOD) and Vocollect Healthcare Systems Announce a 'First in the Industry' Strategic Partnership 3Health News:Women Veterinarians Face Higher Miscarriage Risk 2Health News:Women Veterinarians Face Higher Miscarriage Risk 3Health News:Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Company's 10-Year Anniversary 2Health News:Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Company's 10-Year Anniversary 3Health News:Sonic Innovations Launches Two New Hearing Aid Products in Conjunction With Company's 10-Year Anniversary 4
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
Inquire...
Inquire...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: